Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Equity Income: 2015-2025

Historic Equity Income for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Sep 2025 value amounting to $6,000.

  • Lineage Cell Therapeutics' Equity Income rose 200.00% to $6,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $12,000, marking a year-over-year increase of 144.44%. This contributed to the annual value of -$8,000 for FY2024, which is 95.45% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Equity Income is $6,000, which was up 400.00% from -$2,000 recorded in Q2 2025.
  • Lineage Cell Therapeutics' Equity Income's 5-year high stood at $40,000 during Q1 2023, with a 5-year trough of -$517,000 in Q4 2022.
  • Its 3-year average for Equity Income is -$16,818, with a median of -$5,000 in 2025.
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Equity Income was 316.67% (2024), while the steepest drop was 112.50% (2024).
  • Over the past 4 years, Lineage Cell Therapeutics' Equity Income (Quarterly) stood at -$517,000 in 2022, then surged by 98.84% to -$6,000 in 2023, then spiked by 316.67% to $13,000 in 2024, then skyrocketed by 200.00% to $6,000 in 2025.
  • Its last three reported values are $6,000 in Q3 2025, -$2,000 for Q2 2025, and -$5,000 during Q1 2025.